Neal M. Goldsmith, Ph.D., Rick Doblin, Ph.D., Michael Mithoefer, M.D., and Bill A. Richards, Ph.D.
20% off online discount: use code ONLINE20
We are in the midst of a “psychedelic renaissance” of extraordinary research at Johns Hopkins, Harvard, and other top medical schools. This webinar series will share the powerful findings of this leading-edge research with four leaders in this exciting new work. We will use interactive discussions and audience participation.
MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder (PTSD): Rationale, History and Ongoing Clinical Research
Michael Mithoefer, M.D., Principal Investigator, MAPS MDMA PTSD study
Neal M. Goldsmith, Ph.D., Moderator
Sunday, September 16, 1-3pm EDT
PTSD is a serious public health problem for which existing treatments are often inadequate. MDMA has shown promise as a catalyst to psychotherapy for PTSD in early clinical trials, and is currently being tested in veterans with treatment-resistant PTSD. We will discuss the results of this research, the nature of the therapeutic effects of MDMA and developing research worldwide.